{
    "clinical_study": {
        "@rank": "53731", 
        "arm_group": {
            "arm_group_label": "MEDI4736 & Tremelimumab Treatment", 
            "arm_group_type": "Experimental", 
            "description": "MEDI4736 and Tremelimumab will be administered by IV infusion"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label,  study with a standard 3+3 dose-escalation phase,\n      followed by an expansion phase in subjects with solid tumors"
        }, 
        "brief_title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", 
        "condition": "Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically- or cytologically-confirmed solid tumor with at least one measurable\n             lesion.\n\n          -  Failed to respond to or relapsed following standard treatment, or declined or was not\n             eligible for standard treatment.\n\n          -  ECOG performance status of 0-2.\n\n          -  Anticipated lifespan greater than 6 month.\n\n          -  Adequate organ and marrow function\n\n          -  Able and willing to give valid written informed consent.\n\n          -  Able and willing to give valid written consent for archival tumor samples\n\n          -  Able and willing to give valid written consent for biopsy samples (subjects in the\n             expansion phase only).\n\n        Exclusion Criteria:\n\n          -  Prior exposure to Tremelimumab or MEDI4736 or other anti-CTLA-4, anti-PD-1,\n             anti-PD-L1 antibodies\n\n          -  History of severe allergic reactions to any unknown allergens.\n\n          -  Active or prior autoimmune disease except for autoimmune thyroiditis or vitiligo.\n\n          -  Any prior Grade \u2265 3 immune-related adverse event (irAE) or any prior\n             corticosteroid-refractory irAE.\n\n          -  Known active or chronic viral hepatitis or history of any type of hepatitis within\n             the last 6 months.\n\n          -  History of sarcoidosis syndrome.\n\n          -  Active or history of inflammatory bowel disease (colitis, Crohn's), diverticulitis,\n             irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal\n             conditions associated with diarrhea. Active or history of systemic lupus\n             erythematosus or Wegener's granulomatosis.\n\n          -  Metastatic disease to the central nervous system for which other therapeutic options,\n             including radiotherapy, may be available.\n\n          -  Known immunodeficiency or active HIV.\n\n          -  Participation in any other clinical trial involving another investigational agent\n             within 4 weeks prior to day 1 of the study.\n\n          -  Mental impairment that may compromise the ability to give informed consent and comply\n             with the requirements of the study.\n\n          -  Women who are breast feeding or pregnant\n\n          -  Women of childbearing potential not using a medically acceptable means of\n             contraception for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975831", 
            "org_study_id": "LUD2013-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "MEDI4736 & Tremelimumab Treatment", 
                "intervention_name": "MEDI4736", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEDI4736 & Tremelimumab Treatment", 
                "intervention_name": "Tremelimumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "sbertolini@licr.org", 
            "last_name": "Stephane Bertolini, PharmD", 
            "phone": "2124501587"
        }, 
        "overall_official": {
            "affiliation": "MSKCC", 
            "last_name": "Jedd Wolchok, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration time curve, maximum concentration, clearance, half-life after administration of MEDI4736 and Tremelimumab", 
                "safety_issue": "No", 
                "time_frame": "Up to 15 months"
            }, 
            {
                "measure": "Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 15 months"
            }, 
            {
                "measure": "Tumor Response by the Immune-related Response Criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Tumor Response using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Progression-free Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Ludwig Institute for Cancer Research", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "MedImmune LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Cancer Research Institute, New York City", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ludwig Institute for Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}